FluoroPharma Medical, Inc.
FPMI
$0.00
$0.000.00%
OTC PK
| 12/31/2016 | 09/30/2016 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 22.28% | -22.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 63.17% | -52.96% | |||
| Operating Income | -63.17% | 52.96% | |||
| Income Before Tax | -133.12% | 152.32% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -133.12% | 152.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -133.12% | 152.32% | |||
| EBIT | -63.17% | 52.96% | |||
| EBITDA | -65.46% | 53.82% | |||
| EPS Basic | -198.67% | 128.96% | |||
| Normalized Basic EPS | -142.86% | 139.72% | |||
| EPS Diluted | -324.24% | 112.74% | |||
| Normalized Diluted EPS | -196.00% | 117.73% | |||
| Average Basic Shares Outstanding | 0.94% | 0.86% | |||
| Average Diluted Shares Outstanding | -55.37% | 128.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||